Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is a rare, but aggressive endocrine malignancy with a generally poor clinical outcome. There is no effective therapy for advanced and metastatic ACC. In our study, we found that an existing drug (rottlerin) exerted its tumour-suppressive function in ACC. Specifically,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yi, Wang, Minjie, Zhao, Xu, Zhang, Lei, Wu, Yigao, Wang, Bangqi, Hu, Weilie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410265/
https://www.ncbi.nlm.nih.gov/pubmed/28423559
http://dx.doi.org/10.18632/oncotarget.15221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410265/
https://www.ncbi.nlm.nih.gov/pubmed/28423559
http://dx.doi.org/10.18632/oncotarget.15221

Ejemplares similares